Tarsons Products Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Healthcare Equipment & Supplies | Market Cap: ₹1.8K Cr
Tarsons expects growth driven by new product launches including bioprocess and cell culture products over the next 3 to 5 years. Growth expected through new product launches and market share gains both domestically and internationally, particularly in exports.
From Tarsons Products's Q2 FY26 earnings-call transcript · updated 26 Aug 2026.
Price
₹346
Market Cap
₹1.8K Cr
P/E Ratio
155.0
How does Tarsons Products rank in Healthcare Equipment & Supplies?
Compare Tarsons Products against every Healthcare Equipment & Supplies company this quarter on revenue, margins and earnings-call signals.
Tarsons Products — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹121 Cr, net profit ₹4 Cr.
Full financials →📊 Revenue & Sales Performance
- →Tarsons expects growth driven by new product launches including bioprocess and cell culture products over the next 3 to 5 years.
- →Capacity expansion underway (Panchla and Amta facilities) targeting peak revenue potential of INR350-400 crores, with INR100-125 crores from existing products and the rest from new products.
- →Ramp-up timeline for full utilization is estimated at 3 to 5 years, with gradual market penetration and customer validation.
- →Export market inquiries are strong, with efforts to increase wallet share in both domestic and international markets.
- →Domestic market growth is challenged by high competition and price sensitivity; however, new products and increasing brand recall are expected to support incremental revenue.
- →No planned price cuts; growth is expected to be volume-driven without margin erosion.
- →Plastic labware market is expanding faster than glass, currently at INR1,200 crores, signaling long-term sector growth opportunities.
📈 Profitability & Margins
- →Growth expected through new product launches and market share gains both domestically and internationally, particularly in exports.
- →Capacity expansion at Panchla and Amta facilities to be fully ramped by Q4 FY26, enabling increased production and revenue potential (~INR350-400 crores peak revenue).
- →Ramp-up timelines for capacity expansion and new products projected at 3-5 years.
- →EBITDA margins expected to improve due to higher revenue, favorable product mix, and operating leverage.
- →PAT margins currently affected by higher depreciation but expected to normalize once facilities fully commissioned.
- →Operating cash flow has shown significant improvement, doubling in H1 FY26 compared to the prior year.
- →No explicit EPS guidance provided, but sustained volume growth and margin expansion suggest positive earnings trajectory going forward.
- →External challenges like U.S. tariffs and global freight issues may impact near-term growth, but management remains optimistic.
🏗️ Capital Expenditure Plans
- →Total capex planned between INR550 crores to INR650 crores, covering Panchla, Amta, and existing plants.
- →Panchla facility focused on capacity expansion for existing products and launching new products like cell culture products.
- →Amta facility includes radiation and sterilization plant, with some manufacturing of existing products starting soon.
- →Capex timeline extended due to inflation and foreign exchange fluctuations; expected to be fully commissioned by Q4 FY26.
- →Peak asset turnover estimated at 0.7 to 0.8 on gross block level.
- →Ramp-up for new products expected over 3 to 5 years; existing product expansion over 2 to 3 years.
- →No plans to shut down old facilities; all will operate concurrently.
- →Strategic investment aims at reducing dependency on sole vendors (e.g., in radiation) and increasing operating leverage through sterile goods production.
💰 Fundraising & Capital Structure
- →The company anticipates peak debt on a standalone basis not exceeding INR 350 crores.
- →Total debt on consolidation (including subsidiaries) is expected to peak around INR 425 crores to INR 450 crores.
- →There is no explicit mention of plans for new equity fundraising in the discussed pages.
- →The company is focused on disciplined loan repayment to manage debt levels.
- →Ongoing capital expenditures are being managed with existing financial arrangements; no clear indication of additional external fundraising through debt or equity at this time.
📋 Order Book & Pipeline
- →Tarsons is experiencing a healthy and growing order book across global markets, including the U.S. and other international regions.
- →Some orders are delayed or pending due to capacity constraints and ongoing machine commissioning.
- →Management is optimistic about export growth by the end of the year, expecting to overcome current shipment delays caused by factors like non-issuance of Bills of Lading.
- →Existing customers continue to place orders, with no loss of clients despite tariff challenges.
- →There is a steady flow of inquiries for both existing and new products, especially for ODM contracts, indicating potential future order additions.
- →The company expects gradual ramp-up in order fulfillment as new capacities (Amta and Panchla facilities) come online within 3 to 5 years.
Key Metrics
Continue your research
What Tarsons Products Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Vaidya Sane (Q2 FY26)
Ongoing construction and CAPEX of about INR 25-30 crores for capacity expansion at Khopoli and Nagpur hospitals. Key concall takeaways from Vaidya Sane's Q2…
- Earkart (Q2 FY26)
Earkart has already secured government orders worth approximately ₹9 crores in the current fiscal year (Page 8, 7th excerpt). Key concall takeaways from…
- QMS Medical (Q2 FY26)
The only related transaction noted is the recent acquisition of Saarathi increasing stake from 51% to 76%, but no fundraising details were shared with respect…
- Prevest Denpro (Q2 FY26)
100 crores in revenue within three years. Key concall takeaways from Prevest Denpro Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Tarsons Products Q2 FY26 results?
Tarsons expects growth driven by new product launches including bioprocess and cell culture products over the next 3 to 5 years. Growth expected through new product launches and market share gains both domestically and internationally, particularly in exports.
What is Tarsons Products share price analysis?
Tarsons Products currently shows a neutral. The stock trades at a P/E of 155.0 with a market cap of ₹1,835 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tarsons Products planning capital expenditure?
Total capex planned between INR550 crores to INR650 crores, covering Panchla, Amta, and existing plants.
Keep Tarsons Products on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.